Latest filings (excl ownership)
6-K
Notice of Annual General Meeting
12 Apr 24
6-K
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
11 Apr 24
6-K
Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity’s Horizons in Oncology Virtual Conference
2 Apr 24
20-F
2023 FY
Annual report (foreign)
12 Mar 24
6-K
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
7 Mar 24
6-K
Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
5 Mar 24
6-K
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
4 Mar 24
6-K
Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference
28 Feb 24
6-K
Current report (foreign)
14 Feb 24
6-K
Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors
9 Jan 24
6-K
Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024
4 Jan 24
6-K
Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS
7 Dec 23
6-K
Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy
9 Nov 23
6-K
Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep
9 Nov 23
6-K
Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC
3 Nov 23
6-K
Condensed Interim Consolidated Financial Statements
3 Nov 23
6-K
Oncolytics Biotech® Reports Third Quarter 2023 Financial Results and Operational Highlights
3 Nov 23
6-K
Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO
23 Oct 23
6-K
Oncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the GOBLET Study
23 Oct 23
6-K
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights
20 Oct 23
6-K
Oncolytics Biotech® To Present Two Posters on the Pelareorep-Based GOBLET Study at ESMO 2023
16 Oct 23
6-K
Innovative Multimillion-Dollar Grant Was Created in 2022 to Drive Biopharma Industry to Speed Development of Pancreatic Cancer Therapies
26 Sep 23
6-K
Oncolytics Biotech® Announces Fireside Chat at the Cantor Global Healthcare Conference
19 Sep 23
6-K
Oncolytics Biotech® to Participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference
6 Sep 23
6-K
Condensed Interim Consolidated Financial Statements
14 Aug 23
6-K
Oncolytics Biotech® Reports Second Quarter 2023 Financial Results and Operational Highlights
14 Aug 23
6-K
Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity’s 43rd Annual Growth Conference
4 Aug 23
6-K
Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights
4 Aug 23
6-K
Current report (foreign)
22 Jun 23
6-K
Current report (foreign)
5 Jun 23
6-K
Current report (foreign)
26 May 23
6-K
Current report (foreign)
25 May 23
6-K
Current report (foreign)
11 May 23
6-K
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
10 May 23
6-K
Condensed Interim Consolidated Financial Statements
5 May 23
6-K
Oncolytics Biotech® Reports First Quarter 2023 Financial Results and Operational Highlights
5 May 23
6-K
Current report (foreign)
26 Apr 23
6-K
Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity’s Horizons in Oncology Virtual Conference
12 Apr 23
6-K
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
12 Apr 23
6-K
Oncolytics Biotech® Announces Filing and Mailing of the Management Information Circular in Connection with the Annual General Meeting of Shareholders
12 Apr 23
Latest ownership filings
No filings